Douglas Emmett (NYSE:DEI) Q4 2025 Earnings call February 11, 2026 02:00 PM ET Company ParticipantsJohn Kim - Managing Director - US Real EstateJordan Kaplan - President and CEOKevin Crummy - CIONicholas Yulico - Managing Director, U.S. REIT ResearchPeter Seymour - CFORichard Hightower - Managing DirectorSteve Sakwa - Senior Managing DirectorStuart McElhinney - VP of Investor RelationsConference Call ParticipantsAlexander Goldfarb - Senior REIT Analyst, Managing DirectorBlaine Heck - Executive Director, Seni ...

Financial Data and Key Metrics Changes - Revenue increased by 1.8% to $249 million compared to Q4 2024, driven by both office and multifamily revenues [13] - Funds from Operations (FFO) decreased to $0.35 per share, and Adjusted Funds from Operations (AFFO) decreased to $53 million due to increased interest expenses and lower interest income [13] - Same-property cash Net Operating Income (NOI) decreased by 1.4% for the quarter, primarily due to higher office operating expenses, although multifamily NOI growth partially offset this [13] Business Line Data and Key Metrics Changes - The company achieved 100,000 sq ft of net positive office absorption in Q4, with strong demand and high retention rates [4] - Multifamily segment reported full occupancy and a nearly 5% increase in same-property cash NOI compared to the prior year [4] - The company signed 896 office leases totaling 3.4 million sq ft for the full year of 2025, with 224 office leases covering 906,000 sq ft signed in Q4 [11] Market Data and Key Metrics Changes - Office tenant demand was diversified across various industries, with no single segment exceeding 20% of tenant demand in Q4 [11] - The company noted that financial services, legal, health services, education, and real estate led the demand [11] - The only market that experienced a dip in Q4 was Hawaii, while all other markets in L.A. showed positive movement [102] Company Strategy and Development Direction - The company plans to focus on office leasing and re-tenanting Studio Plaza, with a straightforward strategic plan for 2026 [6] - Construction is set to begin on 10900 Wilshire, converting an existing office tower into residential units, and the Landmark Residences redevelopment is also underway [5][8] - The company aims to capitalize on attractive acquisitions in the current market cycle, believing that current valuations offer significant discounts to long-term values [6][88] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term fundamentals of their markets and the quality of their portfolio, despite acknowledging potential challenges in 2026 [6] - The company remains cautious about occupancy growth, with guidance reflecting increased interest expenses and no assumptions of occupancy growth despite positive Q4 results [13][14] - Management noted that political initiatives and regulations could impact operations and G&A costs in 2026 [51][53] Other Important Information - The company executed nearly $2 billion in debt transactions at competitive rates, extending its maturity profile and strengthening its balance sheet [5] - Management indicated that the anti-rent gouging ordinance has not materially impacted their operations or rent growth [91][94] - The company has significant development sites in Honolulu, with plans to build additional residential units as market conditions align [75] Q&A Session Summary Question: Stock performance and acquisition strategy - Management indicated a preference for acquisitions over stock buybacks, citing concerns about increasing leverage through buybacks [19][21] Question: Market demand and absorption trends - Management expressed hope that positive absorption trends indicate a fundamental shift in market demand, although caution remains for the upcoming year [22][23] Question: Industry consolidation impact - Management does not foresee significant negative impacts from media industry consolidation, believing it may rejuvenate demand for their tenants [29] Question: Development pipeline and yields - Management confirmed that they are actively planning additional residential projects, with expected yields above 8% [34][58] Question: Guidance on straight-line rent and NOI - Management explained that higher straight-line rent guidance reflects existing leases and new leasing activity, but they are not ready to provide specific NOI breakdowns for Studio Plaza [39] Question: UCLA lease expirations and political initiatives - Management clarified that UCLA operates independently across departments, and political initiatives have led to increased G&A costs but have not materially impacted operations [46][51]

Financial Data and Key Metrics Changes - In Q4 2025, Penske Automotive Group generated $7.8 billion in revenue, a decrease of 4% compared to the previous year [9] - Earnings before taxes (EBT) for Q4 was $256 million, with net income at $186 million, resulting in earnings per share of $2.83 [10] - The company reported a total revenue of $31 billion for the year, with net income of $935 million and earnings per share of $14.13 [5][6] - The dividend payout ratio increased to 37.4%, with a forward yield of 3.4% [6][24] Business Line Data and Key Metrics Changes - Automotive same-store units delivered declined by 8%, with used vehicle sales down 4% [9] - Gross profit per unit retailed in Q4 was $4,689, up $47 sequentially, while gross profit per used unit remained consistent at $1,770 [9] - In the commercial truck segment, revenue was $725 million, with EBT declining from $45 million to $34 million year-over-year [14] - The service and parts revenue in the U.S. increased by 6%, with gross profit up by 5.5% [12] Market Data and Key Metrics Changes - In the U.S., retail automotive same-store new and used unit sales decreased by 4%, with new unit sales down 6% and used down 1% [12] - In the U.K., same-store new units delivered were impacted by a 20% decline in sales of German luxury brands [19] - International revenue was $2.8 billion, down 2%, with challenges in the U.K. market due to inflation and consumer affordability [18] Company Strategy and Development Direction - The company is focused on strategic acquisitions, including the purchase of Penske Motor Group, which is expected to generate $2 billion in estimated annualized revenue [6][24] - Penske Automotive Group aims to maintain a strong balance sheet and a disciplined approach to capital allocation, with plans for further acquisitions and divestitures [22][24] - The company is adapting to market conditions in the U.K. by realigning operations and reducing unprofitable locations [18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, anticipating a recovery in the commercial truck market and a stronger macro environment in the U.S. [27] - The company is addressing affordability pressures and consumer behavior changes, particularly in after-sales services [88][92] - Management noted that the freight market is showing signs of improvement, with capacity tightening in certain regions [54] Other Important Information - The company repurchased 1.2 million shares for $182 million, representing 1.8% of outstanding shares [6][24] - Total inventory was $4.8 billion, with a 49-day supply for new vehicles [26] Q&A Session Summary Question: Can you discuss the brand mix trends and strategic direction? - Management confirmed growth in brands like Toyota, Lexus, BMW, and Porsche, particularly in the U.S. and strategic markets like Florida, Texas, and California [30][31] Question: What is the earnings cadence expected for 2026? - Management indicated Q1 will face headwinds due to tariff-related effects, with expectations for a stronger Q2 [35][36] Question: What is the outlook for the parts and service business? - The company expects continued strong growth in the parts and service business, driven by effective labor rate increases and customer pay opportunities [46][48] Question: How is the freight market expected to perform? - Management expressed cautious optimism, noting signs of capacity tightening and potential growth in the freight market [54] Question: What is the strategy regarding Chinese OEMs in international markets? - The company is adapting by incorporating Chinese brands into their Sytner Select stores to understand the market better [95]

Pinnacle Financial Partners Conference Call Summary Company Overview - **Company**: Pinnacle Financial Partners (NasdaqGS:PNFP) - **Event**: 2026 Conference Call - **Date**: February 11, 2026 Key Points Merger and Cultural Integration - The merger with Legacy Synovus has been a focal point over the past 6-9 months, with emphasis on maintaining the Pinnacle model and integrating cultures [3][4] - Pinnacle received 50 Greenwich Awards for client satisfaction, ranking number 1 and number 6 in the country, indicating strong client loyalty despite merger uncertainties [4][5] - Team member engagement is high, with Pinnacle at 93% and Legacy Synovus at 89%, reflecting a positive work environment [4] Incentive Structure - The merger will maintain a geographically based model with a company performance-based incentive plan, which is different from individual incentive plans [6][7] - All team members, approximately 8,500, will receive equity annually and be on the same incentive plan, which was rolled out in Q4 2025 [11][12] - The acceleration of incentive plan costs will result in an additional $30 million expense in 2026, impacting cost synergies [12] Loan Growth Outlook - Loan growth is projected at 9%-11% for 2026, primarily driven by bankers already hired, with a strong performance in Q4 2025 showing 10% loan and deposit growth [24][26] - Legacy Pinnacle achieved 12% loan growth, while Legacy Synovus achieved 8%, indicating a solid foundation for future growth [26][27] - The company is confident in maintaining momentum, with expectations for good loan growth in Q1 2026 [28] Deposit Strategy - Deposit growth will be driven by new bankers bringing over relationships, with a focus on balanced growth [36][38] - The company has capabilities to increase deposits but aims to do so at a manageable cost to maintain net interest margin (NIM) [40] Expense Management and Synergies - The company is targeting $250 million in net synergies from the merger, with a focus on team and client treatment before achieving cost efficiencies [43][44] - There are opportunities for further efficiency improvements beyond the immediate merger synergies, particularly in back-office operations [44][46] Banker Retention and Hiring - Banker retention is a key metric, with a voluntary turnover goal of 7%, which is competitive compared to industry standards [48][49] - The merger has not resulted in significant unexpected attrition, and the company continues to attract new talent due to its positive work environment [50][53] Technology and AI Integration - The company is leveraging AI to improve productivity and reduce manual tasks, with a focus on enhancing banker capabilities [62][63] - AI tools have been deployed for fraud detection and client insights, contributing to a reduction in fraud incidents [64][65] Credit Quality and Market Conditions - Credit quality remains stable, with no systemic issues identified, and expectations for a benign credit environment in 2026 [68] - The company is monitoring commercial real estate (CRE) conditions, anticipating potential growth as the market stabilizes [69] Capital Management - The company has a $400 million capital authorization in place, with plans to accrete capital gradually while assessing economic conditions [70][71] - Current CET1 is estimated at about 10%, with a goal to reach a range of 10.25%-10.75% [71] Conclusion Pinnacle Financial Partners is navigating its merger with Legacy Synovus while maintaining a strong focus on cultural integration, client satisfaction, and growth strategies. The company is optimistic about loan growth, efficient expense management, and leveraging technology to enhance operations. The outlook for credit quality remains stable, and capital management strategies are in place to support future growth.

AIM ImmunoTech Conference Summary Company Overview - AIM ImmunoTech is a late-stage immunopharma company focused on the drug Ampligen (rintatolimod), which has shown efficacy and safety in various solid tumors, particularly in oncology since its repurposing from chronic fatigue syndrome in 2016-2017 [1][2] Core Points and Arguments - **Pancreatic Cancer Focus**: The company is prioritizing the approval of Ampligen for pancreatic cancer, having initiated a program in 2017 with a Dutch government-approved early access program for late-stage patients [2][4] - **Clinical Trials**: Currently conducting a Phase I-II trial combining Ampligen with AstraZeneca's Imfinzi (durvalumab) at Erasmus Medical Center, with approximately 75 subjects treated so far [2][6] - **Mechanism of Action**: Ampligen is described as converting "cold tumors" into "hot tumors" by altering the tumor microenvironment, specifically the ratio of suppressor T cells to killer T cells [3][4] - **Safety Profile**: The drug has a well-established safety profile with over 100,000 IV doses administered, and approvals for various administration methods [4][5] - **Market Opportunity**: The company sees a significant opportunity in the pancreatic cancer market, supported by patent and orphan drug designations that provide market exclusivity [5][6] Key Data and Results - **Survival Benefits**: In the early access program, the median overall survival for 57 subjects was 19.7 months, compared to 12.5 months for the standard of care, resulting in an 8.6-month survival benefit [8][17] - **Quality of Life**: Patients reported significant improvements in quality of life, which is crucial given the poor quality of life associated with late-stage pancreatic cancer [8][19] - **Immunological Markers**: Specific biomarkers, such as the neutrophil-lymphocyte ratio and CA19-9 levels, have been identified as predictive of Ampligen's response and overall survival [9][10] Future Milestones - **DURIPANC Program**: The program aims to treat 25 subjects, with 18 currently in treatment. The last subject is expected to be treated by the end of the year, which will be a significant milestone [20][21] - **Phase III Trial Planning**: The company is already planning for a Phase III trial, with the goal of demonstrating continued positive impacts on survival and quality of life [21][22] Additional Important Information - **Patent Protection**: A recent U.S. patent covering Ampligen in combination with PD-L1 for various cancers is valid until 2039, enhancing the company's market position [5][6] - **Orphan Drug Designation**: This designation provides up to 10 years of market protection in the EU, commencing upon drug approval, which is critical for the company's strategy [6][7] This summary encapsulates the key points from the AIM ImmunoTech conference, highlighting the company's focus on pancreatic cancer, the efficacy and safety of Ampligen, and the strategic planning for future clinical trials and market opportunities.

Summary of Zenas BioPharma Conference Call Company Overview - **Company**: Zenas BioPharma (NasdaqGS: ZBIO) - **Event**: Guggenheim Emerging Outlook Biotech Summit 2026 - **Date**: February 11, 2026 Key Points on IgG4-RD and Obexelimab - **Pipeline Focus**: The primary focus is on obexelimab and its application in IgG4-related disease (IgG4-RD) [2][3] - **INDIGO Phase 3 Study Results**: - Reported a **56% risk reduction** in time to disease flare with a hazard ratio of **0.4** [3] - Approximately **75% of patients** were free from flares, indicating strong efficacy [3] - In the open-label extension, **92% of evaluable patients** remained flare-free at six months [4] - **Safety Profile**: - Serious adverse events were comparable to placebo, with no significant increase in infections [4][5] - The subcutaneous administration showed similar injection site reactions to placebo, enhancing its safety profile [5] Market Research Insights - **Market Research Study**: Conducted with **80 participants**, primarily rheumatologists and gastroenterologists [6] - **Prescribing Likelihood**: - **64%** of physicians indicated they would likely prescribe obexelimab [8] - Expected market share allocation: **47%** for obexelimab, with the remainder split between Uplizna and rituximab [8] - **Patient Population Insights**: - Physicians reported treating an average of **18 patients** per year with IgG4-RD [6] - The drug is seen as suitable for older patients or those with concurrent illnesses [9] Commercialization Strategy - **Market Opportunity**: Estimated market size for IgG4-RD treatment in the U.S. is between **$3-$4 billion**, with expectations for obexelimab to exceed **$1 billion** in sales [41][42] - **Patient Population**: Approximately **20,000 diagnosed patients** in the U.S. currently, with potential for growth through increased education and diagnosis [40] - **Launch Timeline**: - BLA filing expected in **Q2 2026** for the U.S. and in the second half of the year for Europe [56] - Initial launch will feature prefilled syringes, followed by an autoinjector within a year [56] Lupus Program Insights - **Sunstone Study**: - Results expected in **Q4 2026**, focusing on the **BICLA primary endpoint** [62] - Emphasis on strict screening criteria to ensure a pure patient population for accurate results [65] - **Biomarker Program**: A gene pattern identified in **30% of lupus patients** may indicate higher responsiveness to treatment [80] BTK Inhibitor Insights - **Orelibrutinib**: Positioned as a potent option for progressive MS, with ongoing trials to demonstrate its efficacy [90] - **Comparison with Competitors**: Fenebrutinib showed promising results compared to Ocrevus, indicating a competitive landscape for BTK inhibitors [88] Future Developments - **New Molecules**: - TYK2 and IL-17 oral molecules are set to enter clinical trials soon, with promising characteristics noted [95][97] - **Rapid Development**: The IL-17 molecule is expected to move quickly through clinical phases, with outcomes anticipated by the end of the year [97] Conclusion - Zenas BioPharma is positioned to capitalize on its robust pipeline, particularly with obexelimab for IgG4-RD, and is preparing for significant market entry and expansion in the coming years. The company is also actively pursuing additional indications, including lupus and progressive MS, with a focus on safety and efficacy in patient populations.

Summary of Moleculin Biotech Conference Call Company Overview - **Company Name**: Moleculin Biotech (NasdaqCM: MBRX) - **Industry**: Pharmaceutical, specifically focused on cancer treatment - **Stage**: Phase 3 clinical stage with a focus on therapeutic candidates for hard-to-treat tumors and viruses - **Key Product**: Annamycin, a next-generation anthracycline Core Points and Arguments - **Management Experience**: The management team has a combined experience of over 200 years in drug development, with 7 FDA approvals and 14 clinical trials conducted at Moleculin alone [4][5] - **Investment Confidence**: Management has invested approximately $1 million of their own money into Moleculin stock, indicating confidence in the company's future [5] - **Technological Portfolio**: Moleculin has three distinct technologies, all discovered at MD Anderson Cancer Center, with Annamycin being the lead technology [5][6] - **Annamycin's Unique Profile**: - Designed to be non-cardiotoxic, avoiding the 65% chance of permanent heart damage associated with traditional anthracyclines [7] - Demonstrated no evidence of cardiotoxicity in over 100 patients treated, even at high doses [7] - More potent than existing anthracyclines and has fewer severe side effects [7] - **Patent Protection**: Annamycin has composition and matter patent protection through 2040, with potential extensions, and has orphan drug and fast-track status [8] - **Focus on Acute Myeloid Leukemia (AML)**: - Approximately 60% of AML patients are treated with anthracyclines, and Annamycin is positioned to provide a better option for those who cannot tolerate existing treatments [9][10] - Phase 2 trial results showed a 50% complete remission rate in second-line patients, significantly outperforming existing therapies [10][11] Important Developments - **MIRACLE Trial**: - Designed for accelerated approval of Annamycin, with two parts focusing on optimizing dosing and assessing safety and efficacy [12][13] - Early unblinding of data will provide visibility on success likelihood within the first half of the year [14] - Recruitment in Europe is steady, with expectations to reach the first 45 patients soon [15] - **Clinical Trial Results**: - The MB107 trial for Soft Tissue Sarcoma lung metastases showed an overall survival of 13.5 months in heavily pre-treated patients [16] - Annamycin's potential revenue is estimated to be ten times greater than just AML alone due to its applicability across various cancers [16] Market Position and Future Outlook - **Strategic Partnerships**: The company is actively seeking partnerships with big pharma for Annamycin's development, leveraging the expertise of a new strategic advisor from Roche [17] - **Market Cap Potential**: Moleculin is positioned for a market cap breakout, with a strong patent position and promising clinical data [17][18] - **Competitive Landscape**: Annamycin is highlighted as having more near-term visibility and upside potential compared to other Phase 3 assets in the market [18] Additional Insights - **Real-World Impact of Non-Cardiotoxicity**: Clinicians are increasingly recognizing the importance of Annamycin's non-cardiotoxic profile, especially for patients with limited treatment options [20][21] - **Focus on Pediatric AML**: Annamycin could significantly impact pediatric AML patients, who currently have few acceptable treatment options [22] - **Success Metrics for Upcoming Trials**: The primary endpoint for the MIRACLE trial is complete remission after a single cycle, with expectations based on historical data suggesting a 50% complete remission rate [24][25] This summary encapsulates the key points discussed during the conference call, highlighting Moleculin Biotech's strategic direction, product potential, and market positioning.

Summary of VSE Corporation FY Conference Call Company Overview - **Company**: VSE Corporation (NasdaqGS: VSEC) - **Industry**: Aerospace and Defense - **Focus**: Transitioned from a defense contractor to a commercial and business aviation aftermarket-focused business over the last five years, with revenue growth from under $150 million to over $1.1 billion in 2025 [3][4] Key Points and Arguments Transformation and Growth - VSE has undergone a significant transformation, focusing on commercial and business aviation, which has led to substantial revenue growth [3] - The company announced a major acquisition of PAG, which is expected to enhance its MRO (Maintenance, Repair, and Overhaul) capabilities and expand margins to over 20% within 24 months [4] Acquisition Strategy - The PAG acquisition was pursued proactively, with extensive pre-diligence conducted over nearly a year [5][6] - The integration of PAG is expected to create synergies, particularly in cost management, with a clear plan for integration over the next 24 months [28][29] Competitive Landscape - VSE competes with large companies like Boeing, Airbus, HEICO, and AerSale in the distribution segment, and various OEMs in the MRO segment [12][13] - The company has a competitive advantage in the business and general aviation sector, particularly in rotorcraft, due to its extensive capabilities [14] Proprietary Solutions and IP - VSE is developing proprietary content and IP-related work, including OEM solutions and DER (Designated Engineering Representative) repairs, to enhance its service offerings [17][18] - The company aims to support OEMs by providing aftermarket solutions that help them monetize their products effectively [15][21] Market Dynamics - The business and general aviation market is seen as attractive due to its steady growth and the ability to create competitive moats through technical capabilities [36][37] - VSE is focused on building long-term relationships with OEMs, with over 80% of new business wins coming directly from them [16] Supply Chain and Labor Challenges - The company faces ongoing supply chain challenges and a labor shortage in the technical servicing sector, which could impact growth rates [46][47] - VSE is actively managing these challenges by finding alternatives and ensuring efficient operations [46] Financial Outlook - VSE aims to maintain a leverage ratio under 3.5x and expects to be free cash flow positive by 2025, with improved cash flow profiles due to the less working capital-intensive nature of MRO compared to distribution [53][54] - The company is open to pursuing additional acquisitions post-PAG integration, particularly smaller MRO shops that can be integrated quickly [57] Additional Important Insights - Customer reactions to the PAG acquisition have been positive, with excitement around the expanded capabilities and investments in assets [30] - VSE's operational efficiency and technical expertise in distribution are highlighted as key competitive advantages [38][39] - The company is focused on creating a cohesive aftermarket service model that integrates new parts, used parts, and repair services [22][23]

TD Cowen 47th Annual Aerospace & Defense Conference February 11, 2026 I N T R O D U C T I O N Steve Gitlin Vice President, Investor relations 2 This presentation may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be ide ...

Summary of Ameriprise Financial Conference Call Company Overview - **Company**: Ameriprise Financial - **Core Businesses**: - Wealth management with over $1.1 trillion in assets under advisory - Global asset management platform with more than $700 billion in assets under management (AUM) - Insurance business [3][4] Key Points and Arguments Integrated Business Model - Ameriprise emphasizes its integrated business model that leverages capabilities across its three core businesses, contributing to its resilience and growth during various market cycles [4][5] Performance Metrics - Ameriprise has been the best-performing financial stock in the S&P 500 since its spin-off from American Express in 2005 [6][10] Market Sensitivity and Interest Rates - The company has reduced its reliance on short-term earnings to the lowest level possible, anticipating three Federal Reserve interest rate cuts in the current year [12] - Current off-balance sheet short-term cash is approximately $7 billion, with a duration of 3.8 years and an average earning rate of around 5% [12][13] Wealth Management Business - The wealth management business operates on a stewardship model focused on meeting client needs profitably and efficiently [14] - The bank has reached nearly $23 billion in assets, contributing to the profitability of the wealth management segment [15] Competitive Landscape - The competitive environment for financial advisors is described as aggressive, with increased pressure from independent broker-dealers (IBDs) and private equity firms [27][29] - Ameriprise is adjusting its value proposition to attract and retain advisors amidst competitive offers [19][20] Advisor Growth and Net New Assets - The company added 91 advisors last quarter and aims for continued growth, targeting a 4% increase in net new assets [21][22] - Ameriprise has the highest organic advisor growth in the industry, which is crucial for net new asset accumulation [21] General and Administrative Expenses - G&A expenses are expected to grow at a rate of 0%-2%, with a focus on re-engineering processes rather than just cost-cutting [26] Asset Management Business - The asset management segment is working towards positive net flows, with a focus on improving performance and launching new products [58][59] - Approximately 15%-17% of asset management activity is derived from the wealth management business, providing a competitive advantage [56] Insurance Business - The insurance segment has decreased in size but remains important for providing solution sets to clients [60][62] - The company has adjusted its risk profile and is focused on maintaining quality service without pursuing acquisitions in the insurance sector [63][64] Capital Management - Ameriprise has about $2 billion in excess capital and returned 88% of its capital to shareholders through dividends and buybacks in 2025 [66] - The company plans to opportunistically increase buybacks in favorable market conditions while continuing to invest in business growth [67][68] Additional Important Insights - The launch of Signature Wealth aims to enhance the integration of wealth management and asset management services, providing a seamless investment strategy for clients [44][46] - The recent partnership with Huntington Bank, involving $20 billion in assets and 260 financial advisors, highlights Ameriprise's competitive edge in expanding client relationships [49][50] - The company is actively managing its advisor recruitment and retention strategies to ensure competitiveness in a changing market landscape [19][20]